CTOR

Citius Oncology, Inc. Common Stock
CTOR

1.25 USD
+0.06
5.04%
Updated Oct 22, 12:19 PM EDT
1 day
5.04%
5 days
21.36%
1 month
-31.32%
3 months
-60.94%
6 months
-60.94%
Year to date
-60.94%
1 year
-60.94%
5 years
-60.94%
 

About: Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Healthcare Pharmaceutical Preparations
–
Funds holding %
of 6,740 funds
–
Analysts bullish %

Fund manager confidence

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$6
380%
upside
Avg. target
$6
380%
upside
High target
$6
380%
upside

1 analyst rating

1 positive
100%
0 neutral
0%
0 negative
0%
EF Hutton
Jason Kolbert
39% 1-year accuracy
22 / 56 met price target
380%upside
$6
Buy
Maintained
13 Aug 2024
See Analyst Rankings

Financial journalist opinion

We haven’t received any recent news articles for CTOR.

See News Rankings
Charts implemented using Lightweight Charts™